signature is referred to in Dr. Stabinsky’s testimony. The notebook page has the
heading “Synthesis of Tac II promoter and linker for Immune Interferon (For K.
Alton)” and states that:
This linker will be used to express the Immune interferon gene that
lack the first three amino acids (from the N-terminus) through the
Trp control region.
25. Under the portion of the notebook page reading “Witnessed & Understood by
me”, no signature appears. Moreover, we see no witnessing signature elsewhere
on the notebook page. Accordingly, it does not appear that the notebook page
was witnessed.
26. A linker sequence set forth on the notebook page (at FF 24) is the same as the
linker sequence found in the notebook page referred to in Dr. Alton’s testimony
(at FF 17).
The Gray et. al publication
27. Dr. Alton refers to a publication by Gray et al. (“Gray”)9 (Exh. 1011) in his
testimony. (Exh. 1 at ¶ 3).
28. According to the Gray publication, IFN-( has anti-viral and anti-proliferative
effects. (Exh. 1011 at 503).
29. The publication date of Gray is prior to Dr. Alton’s work in October of 1982.
9 Gray et al., Nature, 295:503-508 (Feb. 1982).
10
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007